This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ALS Reviewed By NeuroPerspective

CARDIFF, Calif., Feb. 11, 2013 /PRNewswire/ --  NI Research has released the February issue of NeuroPerspective. The issue features a comprehensive review of ALS, and the continuing but frustrating search for a genuinely useful treatment for the treatment of this devastating illness.

"Just as Alzheimer's slowly erases memory and personality, ALS gradually destroys muscle control, leaving patients almost invariably doomed to death from respiratory failure. The Phase III failure of Biogen-Idec/Knopp's dexpramipexole has provided yet another reminder of how difficult it has been to achieve any headway against ALS," said Harry Tracy, Ph.D., editor and publisher of NeuroPerspective.

The 21-page issue includes: 1) An overview of the pathophysiology of ALS; a reconsideration of SOD1 anomalies in recapitulating phenotype rather than genotype; and the growing interest in therapeutic approaches that address immunoreactive and inflammatory factors.

2) Programs covered in the review include those from Biogen-Idec and Isis Pharmaceuticals,  Neuraltus, Newron, NeuralStem, BrainStorm Cell Therapeutics, Cambria Pharmaceuticals, Regenesance, Amorfix, KineMed, and Cytokinetics, plus many others. The prominent role of ALS TDI in ALS research is noted, as is its intriguing program assessing the potential value of Novartis' Gilenya as an ALS therapeutic.

3) Other coverage and commentary in the February issue includes:

  • Genentech's licensing of the Afraxis PAK program
  • Executive Turbulence at AstraZeneca and EnVivo Pharmaceuticals
  • Teva and Tire Irons: The Risk of Going MAD

A brief summary review of Regenesance, developing therapeutics for disorders associated with complement activation.

The February issue of NeuroPerspective is being made available as a single-issue purchase: $150.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs